Maze Therapeutics (NASDAQ:MAZE) Shares Up 3.5% – Here’s What Happened

Maze Therapeutics, Inc. (NASDAQ:MAZE) shares were up 3.5% on Tuesday . The stock traded as high as $11.71 and last traded at $11.43. Approximately 19,890 shares traded hands during trading, a decline of 93% from the average daily volume of 297,836 shares. The stock had previously closed at $11.04.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MAZE. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They issued an “overweight” rating and a $30.00 price target on the stock. Guggenheim began coverage on Maze Therapeutics in a research report on Tuesday, February 25th. They set a “buy” rating and a $19.00 price target for the company. Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, Leerink Partners started coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set an “outperform” rating and a $28.00 target price for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Stock Up 6.5 %

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.